These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Experimental and clinical studies of BRL 25000 (clavulanic acid-amoxicillin) granules in the field of pediatrics]. Minamitani M; Hachimori K; Kaneda K Jpn J Antibiot; 1985 Feb; 38(2):415-22. PubMed ID: 4009950 [TBL] [Abstract][Full Text] [Related]
24. Augmentin (Amoxycillin and clavulanic acid) in the treatment of urinary tract infections and skin and soft tissue infections. Tan TH; Tay L; Yeo M; Feng PH Singapore Med J; 1983 Oct; 24(5):299-302. PubMed ID: 6669995 [No Abstract] [Full Text] [Related]
25. Amoxicillin-potassium clavulanate: a novel beta-lactamase inhibitor. Smith BR; LeFrock JL Drug Intell Clin Pharm; 1985 Jun; 19(6):415-20. PubMed ID: 3891282 [TBL] [Abstract][Full Text] [Related]
26. Amoxicillin-clavulanic acid (Augmentin). Med Lett Drugs Ther; 1984 Nov; 26(674):99-100. PubMed ID: 6387417 [No Abstract] [Full Text] [Related]
27. Amoxicillin-clavulanate (Clavulin). Infectious Diseases and Immunization Committee, Canadian Paediatric Society. Infectious Diseases and Immunization Committee CMAJ; 1985 Oct; 133(8):739. PubMed ID: 4042055 [No Abstract] [Full Text] [Related]
28. [Effect of BRL 25000 (clavulanic acid-amoxicillin) on bacterial flora in human feces]. Motohiro T; Tanaka K; Koga T; Shimada Y; Tomita N; Sakata Y; Fujimoto T; Nishiyama T; Kuda N; Ishimoto K Jpn J Antibiot; 1985 Feb; 38(2):441-80. PubMed ID: 3847525 [TBL] [Abstract][Full Text] [Related]
29. In-vitro activity of augmentin against clinically important gram-positive and gram-negative bacteria in comparison with other antibiotics. Focht J; Klietmann W; Heilmann HD Zentralbl Bakteriol Mikrobiol Hyg A; 1984 Apr; 256(4):523-30. PubMed ID: 6564828 [TBL] [Abstract][Full Text] [Related]
30. Penicillin gets some help against resistant pathogens. Henehan J JAMA; 1982 Nov; 248(19):2427. PubMed ID: 6922944 [No Abstract] [Full Text] [Related]
31. [In vitro susceptibilities of causative organisms isolated from patients with primary respiratory tract infections to BRL 25000 (clavulanic acid/amoxicillin)]. Deguchi K; Fukayama S; Nishimura Y; Yokota N; Tanaka S; Oda S; Matsumoto Y; Ikegami R; Sato K; Fukumoto T Jpn J Antibiot; 1985 Oct; 38(10):2797-808. PubMed ID: 3878415 [TBL] [Abstract][Full Text] [Related]
32. Distribution of amoxicillin and clavulanic acid in infected animals and efficacy against experimental infections. Boon RJ; Beale AS; Comber KR; Pierce CV; Sutherland R Antimicrob Agents Chemother; 1982 Sep; 22(3):369-75. PubMed ID: 7137980 [TBL] [Abstract][Full Text] [Related]
33. Amoxicillin and potassium clavulanate: an antibiotic combination. Mechanism of action, pharmacokinetics, antimicrobial spectrum, clinical efficacy and adverse effects. Weber DJ; Tolkoff-Rubin NE; Rubin RH Pharmacotherapy; 1984; 4(3):122-36. PubMed ID: 6739312 [TBL] [Abstract][Full Text] [Related]
34. Intravenous Augmentin in bacteraemia and severe invasive polymicrobial sepsis. Mehtar S; Ball AP J Antimicrob Chemother; 1985 Jun; 15(6):765-71. PubMed ID: 4030538 [TBL] [Abstract][Full Text] [Related]
35. Comparative activity of BRL 25.000 with amoxycillin against resistant clinical isolates. Van Landuyt HW; Pyckavet M; Lambert AM J Antimicrob Chemother; 1981 Jan; 7(1):65-70. PubMed ID: 6907270 [No Abstract] [Full Text] [Related]
36. The efficacy of augmentin as a beta-lactam antibiotic in surgical and medical practice. Kirei BR; Mhalu FS; Pallangyo PK; Seif SA East Afr Med J; 1987 Jul; 64(7):499-503. PubMed ID: 3691365 [No Abstract] [Full Text] [Related]